These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1970550)

  • 21. Understanding schizophrenia: the impact of novel antipsychotics.
    Remington G
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S29-32. PubMed ID: 8564914
    [No Abstract]   [Full Text] [Related]  

  • 22. L-deprenyl in treating negative symptoms of schizophrenia.
    Perenyi A; Goswami U; Frecska E; Arató M; Bela A
    Psychiatry Res; 1992 May; 42(2):189-91. PubMed ID: 1352903
    [No Abstract]   [Full Text] [Related]  

  • 23. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
    Himelhoch S; Taylor SF; Goldman RS; Tandon R
    Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
    [No Abstract]   [Full Text] [Related]  

  • 24. The relationship of the brief psychiatric rating scale to neuropsychological deficits in phenothiazine-treated schizophrenics.
    Golden CJ; Carpenter B; Wilkening G; Ruedrich S; Chu CC; Graber B
    Psychopharmacol Bull; 1983; 19(3):513-7. PubMed ID: 6138799
    [No Abstract]   [Full Text] [Related]  

  • 25. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
    Friedman J; Ault K; Powchik P
    Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with a drug-free month in schizophrenic outpatients.
    Heinrichs DW; Carpenter WT
    Psychopharmacol Bull; 1985; 21(1):117-9. PubMed ID: 2858904
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical symptomatology and drug compliance in schizophrenic patients.
    Bartkó G; Herczeg I; Zádor G
    Acta Psychiatr Scand; 1988 Jan; 77(1):74-6. PubMed ID: 2894746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroquel and cognitive improvement in patients with schizophrenia.
    Stip E; Lussier I; Babai M; Fabian JL; Link C
    Biol Psychiatry; 1996 Sep; 40(5):434-5. PubMed ID: 8874852
    [No Abstract]   [Full Text] [Related]  

  • 29. Is clozapine response different in neuroleptic nonresponders vs partial responders?
    Osser DN; Albert LG
    Arch Gen Psychiatry; 1990 Feb; 47(2):189-90. PubMed ID: 1967927
    [No Abstract]   [Full Text] [Related]  

  • 30. Clozapine augmented with aripiprazole in 5 patients with schizophrenia.
    Abu-Tair F; Kopitz J; Bergemann N
    J Clin Psychopharmacol; 2006 Dec; 26(6):669-71. PubMed ID: 17110831
    [No Abstract]   [Full Text] [Related]  

  • 31. Piperacetazine in ambulatory chronic schizophrenic patients.
    Rada RT; Donlon PT
    Curr Ther Res Clin Exp; 1974 Feb; 16(2):124-9. PubMed ID: 4156665
    [No Abstract]   [Full Text] [Related]  

  • 32. Clozapine plus lamotrigine in treatment-resistant schizophrenia.
    Dursun SM; McIntosh D; Milliken H
    Arch Gen Psychiatry; 1999 Oct; 56(10):950. PubMed ID: 10530638
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia.
    Jhamnani K; Shivakumar V; Kalmady S; Rao NP; Venkatasubramanian G
    J Neuropsychiatry Clin Neurosci; 2013; 25(1):E06-7. PubMed ID: 23487204
    [No Abstract]   [Full Text] [Related]  

  • 34. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective].
    Windgassen K
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099
    [No Abstract]   [Full Text] [Related]  

  • 36. Untreated psychosis and long-term outcome in schizophrenia.
    Waddington JL; Scully PJ
    Schizophr Bull; 1998; 24(1):34-5. PubMed ID: 9502545
    [No Abstract]   [Full Text] [Related]  

  • 37. Simple schizophrenia in an adolescent.
    Valentí M; Castro-Fornieles J; Lázaro ML; Sugrañes G; Baeza I
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):589-90. PubMed ID: 19877985
    [No Abstract]   [Full Text] [Related]  

  • 38. Information processing and maintenance dose requirements in schizophrenia.
    Marder SR; Asarnow RF; Van Putten T
    Psychopharmacol Bull; 1988; 24(2):247-50. PubMed ID: 2905506
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials.
    McMahon RP; Kelly DL; Kreyenbuhl J; Kirkpatrick B; Love RC; Conley RR
    Neuropsychopharmacology; 2002 Apr; 26(4):537-45. PubMed ID: 11927178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia?
    König P; Conca A; Lugmayer B
    Neuropsychobiology; 1999 Sep; 40(3):140-1. PubMed ID: 10494049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.